重新审视前列腺特异性抗原(PSA)密度:定义最佳PSA范围及适用人群以通过扩大模板活检预测前列腺癌
前瞻性队列中1290例男性接受扩大模板活检,比较PSA密度与PSA在不同PSA范围及既往活检状态下的预测准确性。PSA密度在PSA 4-10 ng/mL和>10 ng/mL时对任何前列腺癌的预测优于PSA,且在既往活检阴性者中增量差异更大;对显著前列腺癌结果类似。
要点
- PSA密度在PSA 4-10 ng/mL时预测任何前列腺癌的AUC为0.70,优于PSA的0.53(P<.0001)。
- PSA密度在PSA>10 ng/mL时预测任何前列腺癌的AUC为0.84,优于PSA的0.65(P<.0001)。
- 既往活检阴性者中PSA密度较PSA的AUC增量差异更大(AUC 0.69 vs 0.55,P<.0001)。
核心结论
- 随着PSA升高,PSA密度相比单独PSA成为更好的前列腺癌预测标志物。
- PSA密度在既往活检阴性男性中预测表现优于PSA。
研究设计与样本
- 前瞻性试验纳入男性,在美国26个中心接受扩大模板活检以评估前列腺癌。
- 共1290例患者,其中585例(45%)诊断为前列腺癌,284例(22%)为显著前列腺癌。
主要发现
- 在PSA 4-10 ng/mL范围内,PSA密度预测任何前列腺癌的AUC为0.70,PSA为0.53(P<.0001)。
- 在PSA>10 ng/mL范围内,PSA密度预测任何前列腺癌的AUC为0.84,PSA为0.65(P<.0001)。
- 在无既往活检男性中,PSA密度预测任何前列腺癌的AUC为0.73,PSA为0.67(P<.0001)。
- 在有既往活检男性中,PSA密度预测任何前列腺癌的AUC为0.69,PSA为0.55(P<.0001);既往活检阴性者中AUC增量差异更高。
- 所有分析中显著前列腺癌结果类似。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the predictive accuracy of prostate-specific antigen (PSA) density vs PSA across different PSA ranges and by prior biopsy status in a prospective cohort undergoing prostate biopsy. MATERIALS AND METHODS: Men from a prospective trial underwent an extended template biopsy to evaluate for prostate cancer at 26 sites throughout the United States. The area under the receiver operating curve assessed the predictive accuracy of PSA density vs PSA across 3 PSA ranges (<4 ng/mL, 4-10 ng/mL, >10 ng/mL). We also investigated the effect of varying the PSA density cutoffs on the detection of cancer and assessed the performance of PSA density vs PSA in men with or without a prior negative biopsy. RESULTS: Among 1290 patients, 585 (45%) and 284 (22%) men had prostate cancer and significant prostate cancer, respectively. PSA density performed better than PSA in detecting any prostate cancer within a PSA of 4-10 ng/mL (area under the receiver operating characteristic curve [AUC]: 0.70 vs 0.53, P < .0001) and within a PSA >10 mg/mL (AUC: 0.84 vs 0.65, P < .0001). PSA density was significantly more predictive than PSA in detecting any prostate cancer in men without (AUC: 0.73 vs 0.67, P < .0001) and with (AUC: 0.69 vs 0.55, P < .0001) a previous biopsy; however, the incremental difference in AUC was higher among men with a previous negative biopsy. Similar inferences were seen for significant cancer across all analyses. CONCLUSION: As PSA increases, PSA density becomes a better marker for predicting prostate cancer compared with PSA alone. Additionally, PSA density performed better than PSA in men with a prior negative biopsy.
引用
- Jue JS, Barboza MP, Prakash NS, et al. Re-examining Prostate-specific Antigen (PSA) Density: Defining the Optimal PSA Range and Patients for Using PSA Density to Predict Prostate Cancer Using Extended Template Biopsy. Urology. 2017. PMID: 28431993. doi:10.1016/j.urology.2017.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。